<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4705">
  <stage>Registered</stage>
  <submitdate>13/11/2014</submitdate>
  <approvaldate>13/11/2014</approvaldate>
  <nctid>NCT02292719</nctid>
  <trial_identification>
    <studytitle>A Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir With Sofosbuvir With and Without Ribavirin in Adults With Chronic Hepatitis C Virus Infection</studytitle>
    <scientifictitle>A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of the Co-Administration of Ombitasvir/ABT-450/Ritonavir (Ombitasvir/ABT-450/r) With Sofosbuvir (SOF) With or Without Ribavirin (RBV) in Subjects With Genotype 2 Chronic Hepatitis C Virus (HCV) Infection or Genotype 3 HCV Infection With or Without Cirrhosis</scientifictitle>
    <utrn />
    <trialacronym>Quartz II/III</trialacronym>
    <secondaryid>2014-003147-35</secondaryid>
    <secondaryid>M14-567</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Chronic Hepatitis C Virus Infection</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Studies of infection and infectious agents</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Sexually transmitted infections</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Ombitasvir/ABT-450/r
Treatment: drugs - Sofosbuvir
Treatment: drugs - Ribavirin (RBV)

Experimental: Arm A:Ombitasvir/ABT-450/r and sofosbuvir (SOF) - Ombitasvir/ABT-450/r and sofosbuvir (SOF) once daily for 12 weeks

Experimental: Arm B;Ombitasvir/ABT-450/r with sofosbuvir (SOF) and ribavirin - Ombitasvir/ABT-450/r with sofosbuvir (SOF) once daily and ribavirin twice daily for 12 weeks

Experimental: Arm C:Ombitasvir/ABT-450/r with sofosbuvir (SOF) and ribavirin - Ombitasvir/ABT-450/r with sofosbuvir (SOF) once daily and ribavirin twice daily for 8 weeks

Experimental: Arm D:Ombitasvir/ABT-450/r with sofosbuvir (SOF) and ribavirin - Ombitasvir/ABT-450/r with sofosbuvir (SOF) once daily and ribavirin twice daily for 6 weeks

Experimental: Arm E;Ombitasvir/ABT-450/r with sofosbuvir (SOF) and ribavirin - Ombitasvir/ABT-450/r with sofosbuvir (SOF) once daily and ribavirin twice daily for 12 weeks

Experimental: Arm F:Ombitasvir/ABT-450/r and sofosbuvir (SOF) - Ombitasvir/ABT-450/r and sofosbuvir (SOF) once daily for 12 weeks


Treatment: drugs: Ombitasvir/ABT-450/r
Tablet

Treatment: drugs: Sofosbuvir
Tablet

Treatment: drugs: Ribavirin (RBV)
Tablet

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Percentage of participants with sustained virologic response 12 weeks (SVR12) post-treatment - Hepatitis C virus ribonucleic acid less than the lower limit of quantification.</outcome>
      <timepoint>12 weeks after the last dose of active drug</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of participants with on-treatment virologic failure - Hepatitis C virus ribonucleic acid greater than or equal to the lower limit of quantification after hepatitis C virus ribonucleic acid less than lower limit of quantification or confirmed 1 log10 IU/mL increase from nadir in hepatitis C virus ribonucleic acid at any time point during treatment, or failure to suppress during treatment with at least 6 weeks of treatment (defined as active study drug duration = 36 days) of treatment for 12-week and 8-week treatment or at least 26 days of treatment for 6-week treatment.</outcome>
      <timepoint>Up to Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of participants with virologic relapse after treatment - Hepatitis C Virus (HCV) ribonucleic acid (RNA) confirmed greater than or equal to the lower limit of quantification between the end of treatment and 12 weeks post treatment among subjects completing treatment and with HCV RNA less than the lower limit of quantification at the end of treatment.</outcome>
      <timepoint>Up to 12 weeks after the last actual dose of active study drug</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Chronic HCV infection prior to study enrollment.

          2. Screening laboratory results from the central clinical laboratory indicating HCV
             genotype 2 or 3 infection only (no mixed genotype).

          3. Absence OR presence of cirrhosis.

          4. If cirrhotic, need to have compensated cirrhosis and absence of hepatocellular
             carcinoma (HCC)</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>99</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Positive screen for hepatitis B surface antigen or anti-human immunodeficiency virus
             antibody

          2. Recent (within 6 months prior to study drug administration) history of drug or alcohol
             abuse.

          3. Current enrollment in another clinical study, previous enrolment in this study, or
             previous use of any investigational or commercially available anti-HCV therapy (other
             than interferon, pegIFN, RBV, and or SOF) including previous exposure to telaprevir,
             boceprevir, ABT-450, or ombitasvir (ABT-267).

          4. Subjects without cirrhosis: Any current or past clinical evidence of cirrhosis.

          5. Abnormal lab tests.

          6. Females who are pregnant or plan to become pregnant or breastfeeding, or males whose
             partners are pregnant or planning to become pregnant</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>19/12/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>70</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>14/07/2017</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Royal Adelaide Hospital /ID# 132014 - Adelaide</hospital>
    <postcode>5000 - Adelaide</postcode>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Edmonton</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Grafton</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>AbbVie</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to evaluate the safety and efficacy of ombitasvir/ABT-450/r with
      sofosbuvir with or without ribavirin in adults with Genotype 2 Chronic Hepatitis C Virus
      (HCV)infection or Genotype 3 HCV infection With or Without Cirrhosis.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02292719</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Mariem Charafeddine, MD</name>
      <address>AbbVie</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>